Study title: Double blind, placebo-controlled, multicenter trial with 2 parallel groups: efficacy and safety assessment of cetirizine in children aged 2 to 12 years (5 mg po: 10 drops for children aged [2 - 6] years and 10 mg po: 20 drops for children aged [6 - 12] years suffering from perennial allergic rhinitis treated for 28 days.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Immune System Diseases | |||||
Brands: | |||||
MAH holders: | |||||
Assessment: | |||||
Active substance: CETIRIZINE | |||||
ATC code: | |||||
Document link: 9918 - Cetirizine - RRCE01L1304.pdf | |||||
Document date: 2011-11-28 | |||||
Study number: RRCE01L1304 | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |